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Treatment Paradigms for the
Superficial Femoral Artery
Are They A-Changin?*
Dierk Scheinert, MD
Leipzig, Germany
The main limitation of endovascular treatment modalities in
the femoropopliteal tract is the high rate of recurrent lesions
necessitating repeat interventions. Although 1-year patency
rates of plain balloon angioplasty might be as low as 30% to
40% (1), improved results have been reported with a primary
stenting approach. Nevertheless, depending on the lesion
length, in-stent-restenosis rates at 1 year are still in the
range of 20% to 40% (2–5). Particularly in longer lesions,
the occurrence of stent fractures seems to contribute to the
development of in-stent-restenosis and has the potential to
further complicate subsequent endovascular procedures (6).
See page 331
Due to the chronic nature of peripheral arterial disease
and the high restenosis rate, in many patients with femo-
ropopliteal obstructions repeat interventions are an essential
part of the long-term treatment strategy. The concept of
saving more options for the future is an important consid-
eration favoring nonstent-based treatment modalities in an
attempt to limit the problem of in-stent-restenosis treat-
ment. From that perspective a treatment alternative that
effectively inhibits the restenosis process after balloon an-
gioplasty, achieving an improved clinical outcome with
minimal need for stent implantation, would be an important
step forward.
In this issue of JACC: Cardiovascular Interventions,
icari et al. (7) report the first single-arm study results
ith a drug-coated balloon (DCB) catheter with urea as
rug carrier and dissolvent and paclitaxel as the active
ubstance. Their data are generally in line with the
lready published THUNDER (Local Taxane with Short
xposure for Reduction of Restenosis in Distal Arteries)
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coated balloons with the contrast agent iopromide as an
additive resulted in a significantly reduced neointimal pro-
liferation as measured by late lumen loss at 6-month
angiographic follow-up (8,9). Beyond this technical proof of
concept, the paper by Micari et al. (7) reports on the
currently largest cohort in the published data with DCB for
femoropopliteal disease. A total of 105 patients have been
successfully treated, with only 12.3% of lesions requiring
stenting. Ninety-two patients have completed the 12-
month follow-up, demonstrating a primary patency rate of
83.7% and a reintervention rate as low as 7.6%.
Despite the obvious study limitations inherent in the
single-arm design and the lack of independent data adjudi-
cation, the authors have to be congratulated for these
outstanding results, which strongly support the concept that
DCB might be a powerful treatment alternative for femo-
ropopliteal disease. It has to be noted that these results were
achieved in a cohort of patients with a mean lesion length of
76.3 mm and almost two-thirds of patients were classified as
moderately or severely calcified. In that context the bailout
stent rate of only 12.3% is remarkably low—probably
achieved by a very high dedication of the investigators to an
optimized PTA technique using prolonged balloon infla-
tions (mean inflation time 181 s). Although the obvious
reluctance of the investigators to implant stents resulted in
a somewhat higher rate of patients with residual stenoses
30% (technical success rate 89.6%), this does not seem to
interfere negatively with the outcome at 12 months. This is
reassuring for the concept of limiting the use of stents after
DCB treatment as much as possible.
Are DCBs going to shift treatment paradigms for the
SFA away from stenting to nonstent-based treatments? It is
certainly too early to draw final conclusions from the
available published data. Although the report by Micari
et al. (7) might be an important piece in the puzzle, we have
to face the fact that the total reported experience of
DCB-treated patients in the SFA is on 200 patients so
far. Clearly, the primary patency rate of 83.7% in a patient
cohort with a mean lesion length of 76.3 mm compares very
favorably with reported results on primary stenting. Never-
theless, direct randomized head-to-head comparisons will
be necessary to ensure comparability of the treatment
groups. Only this approach will allow investigators to obtain
reliable data that might eventually guide us in these impor-
tant treatment decisions.
The real challenge and “unmet clinical need” for inter-
ventional treatment of femoropopliteal lesions are clearly
long lesions and chronic total occlusions of the SFA. This is
the specific subcategory of lesions that continues to repre-
sent a major challenge for currently available endovascular
treatment approaches. In particular, primary stenting with
conventional nitinol stents did not show convincing patency
rates, and stent fractures have been most prevalent in long
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340stented segments (6). This might indicate that nonstent-
based solutions would be particularly desirable for long
lesions. However, will DCB have the potential to be a
primary choice treatment for such lesions? For the moment
we have to admit that almost nothing is known to date
about the potential of DCB treatment for those complex
lesions. In that regard, it will be very important that future
studies will specifically address this complex subgroup of
patients.
In particular, the effectiveness of the combination of
DCB with stenting is currently unclear. At least theoreti-
cally, there are concerns that the biological effect of the
single drug delivery by the DCB might be outweighed by
the chronic proliferation stimulus induced by the implanted
stent. This results in the current paradigm to avoid stenting
as much as possible after DCB treatment. In fact, the study
by Micari et al. (7) has shown that this approach can give
excellent results for short- to intermediate-length lesions.
However, on the basis of experience with conventional
balloon treatment, it is likely that with increasing complex-
ity of the lesion the need for a mechanical stabilization of at
least part of the treated segment might become necessary.
Therefore, the combination of DCB with spot stenting
might be an important concept to explore as a treatment
modality for long segment disease. Alternatively, other
combination therapies like atherectomy followed by DCB
might be viable options and need further evaluation. Last
but not least, with the paclitaxel-coated Zilver PTX stent
(Cook Medical, Bloomington, Indiana), there is a drug-
eluting stent becoming available that has not only been
proven to have significantly better patency rates than PTA
and the bare Zilver stent (10) but has also shown very
encouraging results in long lesions (11). Particularly for
complex lesions, this technology might be a strong compet-
itor to DCB.
Yes, paradigms for interventional treatment of the SFA
are changing—away from a primarily mechanical approach
with ballooning and stenting, toward a more differentiated
physiological treatment. Likely, antiproliferative drug deliv-
ery will have an important role in the future to optimize
long-term outcomes. To what extent such treatment algo-
rithms will still rely on mechanical treatment modalities,
including stent placement as a bailout or as a drug deliveryplatform, remains to be determined. It is time for more
good clinical research!
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